Skip to content

Released Aug 6, 2024, after the close

10-Q filed Aug 6, 2024, 37 days after period end · 0001764013-24-000148

Q1 2025 · 10-Q
Revenue—
Net Income-$87.15MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.60N/M vs Q1 2024no prior Q4 2024 on file
Operating Cash Flow-$76,199,000N/M
Free Cash Flowderived-$76,381,000N/M

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Net Income-$87.15M-$73.94M-$40.37M-$30.47M
EPS Diluted-$0.60-$0.57-$0.35-$0.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR